Advanced Filters
noise
Found 64,783 clinical trials
J Jette Lautrup Frederiksen, Prof, MD

Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2

The goal of this trial is to investigate the biological effects of oral supplementation with indole-3-propionic acid (IPA) taken twice daily in healthy adults. The main scientific questions are: Does supplementation with IPA increase the abundance of regulatory T cells in the blood? Regulatory T cells are believed to play …

18 - 65 years of age All Phase N/A
M Maria Stefania De Simone, Dr

REducing the Risk of COgnitive DEcline ad Dementia in Patients With Subjective Cognitive Decline Through an Immersive Virtual Reality and Telemedicine-based Multi-component Intervention: the SCD-ReCODED Study

Older adults with subjective cognitive decline (SCD) are at high risk of developing dementia and frequently experience subclinical symptoms (e.g., anxiety, depression) which are themselves associated with dementia and cognitive decline risk. To date, the lack of effective disease-modifying treatments, along with the reliable identification of modifiable lifestyle risk factors …

55 - 80 years of age All Phase N/A
L Lung-Ji Chang, Ph.D

Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD

This is a Phase I/II clinical trial of gene therapy for treating Metachromatic leukodystrophy (MLD) using a safety and efficacy improved self-inactivating lentiviral vector TYF-ARSA to transduce patient-derived hematopoietic stem cells (HSCs), with the goal of achieving therapeutic gene correction through transplantation of genetically modified HSCs. The primary objectives are …

1 - 50 years of age All Phase N/A
V Vin Tangpricha, MD, PhD

Progesterone in Gender Affirming Hormone Therapy Study

This study aims to study the effects of Oral Progesterone in Transgender Women. The primary goal is to study the effect of progesterone on psychological distress and secondarily on sleep quality, breast size, quality of life and gender congruence and cardiovascular risk.

18 - 60 years of age Male Phase 2
M Maysara Abdelhaleem Bayuomy, Assist.Prof.

The Effect of Body Mass Index on Short-term Results of HTO

The knee joint plays a major role in weight transmission of the body in day-to-day activities. The biomechanics of the knee and malalignment in lower limb anatomy are major risk factors for chronic knee pain, leaving Total Knee Arthroplasty (TKA) as the best and most successful option for patients with …

40 - 60 years of age All Phase N/A
K Kezhong Zhang

Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients

This study is a randomized, double-blind, controlled trial exploring the effects of long-term taVNS intervention in patients with early-stage Parkinson's disease.

55 - 75 years of age All Phase N/A
S Site Contact

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.

18 years of age All Phase N/A

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose[s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (type …

18 years of age All Phase 1
E Evgeny Levenko

Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa)

A Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.

18 - 75 years of age All Phase 1/2
C Claudia Romero de los Reyes

SPY003-207 in Healthy Volunteers

This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.

18 - 60 years of age All Phase 1

Simplify language using AI